Cinacalcet-clinical and laboratory effectiveness, concomitant treatment patterns and treatment cost: Could we do better and how?

Kidney and Blood Pressure Research

Volumn 33, Issue 5, 2010, Pages 333-342

  Smrová, Jana ^a,b   Urbánek, Tomá ^c  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b INMED ^*  (Czech Republic)

^c INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

Chronic kidney failure; Cinacalcet; Dialysis, cost of; Hyperparathyroidism, secondary; Itching; Phosphate binders; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CINACALCET; LANTHANUM CARBONATE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

ABDOMINAL PAIN; ADULT; ARTICLE; CALCIUM METABOLISM; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COLLAPSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PRURITUS; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; VOMITING;

ADULT; AGED; CALCIUM; CZECH REPUBLIC; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHATES; PROSPECTIVE STUDIES; QUESTIONNAIRES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 77955530416     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317935     Document Type: Article

References (30)

1. Cannata-Andía J, Carrera F: The pathophys-iology of secondary hyperparathyroidism and the consequences of uncontrolled mineral metabolism in chronic kidney disease: the role of COSMOS. NDT Plus 2008; 1(suppl 1):i2-i6.
2. Smrová J: Hyperphosphatemia-a serious complication of chronic renal insufficiency and end-stage renal disease. 1st part-etio-pathogenesis, consequences, and diagnostics (in Czech). Vnitr Lek 2005; 51: 327-335.
3. Block GA, Klassen PS, Lazarus JM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
4. Ganesh SK, Stack AG, Lewin NW et al: Association of elevated serum PO(4), Ca ! PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemo-dialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138.
5. Moe SM, Drueke TB: Management of secondary hyperparathyroidism-the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 2003; 23: 369-379.
6. Olgaard K (ed): Clinical Guide to Bone and Mineral Metabolism in CKD. New York, National Kidney Foundation, 2006.
7. Nemeth EF, Steffey ME, Hammerland LG, et al: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998; 95: 4040-4045.
8. Frazão J, Rodriguez M: Secondary hyper-parathyroidism disease stabilization following calcimimetic therapy. NDT Plus 2008; 1(suppl 1):i12-i17.
9. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(suppl 3):1-201.
10. Block GA, Martin KJ, de Francisco AJ, et al: Cinacalcet for secondary hyperparathyroid-ism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525.
11. Lindberg JS, Culleton B, Wong G, et al: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroid-ism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J am Soc Nephrol 2005;16:800-807.
12. Meola M, Petrucci I, Barsotti G: Long-term cinacalcet treatment and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009; 24: 982-989.
13. Riccardi D, Martin D: The role of calcium-sensing receptor in the pathophysiology of secondary hyperparathyroidism. NDT Plus 2008; 1(suppl 1):i7-i11.
14. Rychlík I, Lopot F: Statistical yearly report on dialysis treatment in the Czech Republic in 2008 (in Czech). http://www.nefrol.cz/in-dex. php?&desktop=clanky&action=view& id=500. Accessed on November 6, 2009.
15. Couttenye MM, D'Haese PC, Verschoren WJ, et al: Low bone turnover in patients with renal failure. Kidney Int 1999; 56(suppl 73):S70-S76.
16. Arenas MD, Alvarez-Ude F, Gil MT, et al: Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007; 22: 1639-1644. (Pubitemid 47073763)
17. St Peter WL, Li Q, Lie J, et al: Cinacalcet use pattern and effects on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 2009; 4: 354-360.
18. Ureña P, Jacobson SH, Zitt E, et al: Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice-the ECHO observational study. Nephrol Dial Transplant 2009; 24: 2852-2859.
19. Moe SM, Chertow GM, Coburn JW, et al: Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760-771.
20. Moe SM, Cunningham J, Bommer J, et al: Long-term treatment of secondary hyper-parathyroidism with the calcimimetic cina-calcet HCl. Nephrol Dial Transplant 2005; 20: 2186-2193.
21. Lazar E, Herbert K, Poma T, Stankus N: Long-term outcomes of cinacalcet and pari-calcitol titration protocol for treatment of secondary hyperparathyroidism. Am J Nephrol 2007; 27: 274-278.
22. Messa P, Macário F, Yaqoob M, et al: The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3: 36-45.
23. Danese MD, Belozeroff V, Smirnakis G, et al: Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1423-1429.
24. Mix TC, St Peter WL, Ebben J, et al: Hospi-talization during advancing chronic kidney disease. Am J Kidney Dis 2003; 42: 972-981.
25. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 67: 467-476.
26. Joy MS, Karagiannis PC, Peyerl FW: Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct cost of treatment. J Manag Care Pharm 2007; 13: 397-411.
27. Narayan R, Perkins RM, Berbano EP, et al: Parathyroidectomy versus cinacalcet hydro-chloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007; 49: 801-813.
28. Garside R, Pitt M, Anderson R, et al: The effectiveness and cost-effectiveness of cinacal-cet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-167.
29. Chertow GM, Pupim LB, Block GA, et al: Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007; 2: 898-905.
30. Cunningham J, Floege J, London G, et al: Clinical outcomes in secondary hyperpara-thyroidism and the potential role of calcimi-metics. NDT Plus 2008; 1(suppl 1):i29-i35.